- |||||||||| NPI-002 / Nacuity Pharma
Trial completion date, Trial primary completion date: NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - Nov 14, 2024
P1/2, N=30, Recruiting,
Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: Mar 2025 --> Jun 2025 Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Trial completion date, Trial primary completion date: INCA: PK and PD Study of NPI-001 and Cysteamine Bitartrate (clinicaltrials.gov) - Nov 13, 2024
P1/2, N=12, Recruiting,
Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: May 2024 --> Apr 2025
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Trial primary completion date: INCA: PK and PD Study of NPI-001 and Cysteamine Bitartrate (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=12, Recruiting,
Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: May 2024 --> Apr 2025 Trial primary completion date: Dec 2023 --> May 2024
- |||||||||| NPI-002 / Nacuity Pharma
Trial completion date, Trial primary completion date: NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=30, Recruiting,
Trial primary completion date: Dec 2023 --> May 2024 Trial completion date: Apr 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Oct 2024
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Enrollment closed, Trial completion date: Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (clinicaltrials.gov) - Feb 8, 2024
P1/2, N=49, Active, not recruiting,
Trial completion date: Apr 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Oct 2024 Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> May 2025
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Enrollment open: INCA: PK and PD Study of NPI-001 and Cysteamine Bitartrate (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=12, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> May 2025 Not yet recruiting --> Recruiting
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Preclinical, Journal: N-Acetylcysteine amide (NACA) and dinaca inhibit HO-INDUCED cataract formation ex VIVO IN pig and rat lenses. (Pubmed Central) - Aug 28, 2023
Based on LC-MS/MS analyses, NACA-induced reduction in opacity observed in rat lenses was attributed to enhanced cysteine and GSH levels while the diNACA-induced reduction in opacity induced did not consistently increase cysteine, cystine and GSH levels and, therefore, appears to involve a different antioxidant mechanism. These screening studies warrant further testing of NACA and diNACA as anticataract agents.
- |||||||||| NPI-002 / Nacuity Pharma
Trial completion date, Trial primary completion date: NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - Mar 21, 2023
P1/2, N=30, Recruiting,
These screening studies warrant further testing of NACA and diNACA as anticataract agents. Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Trial completion date, Trial primary completion date: Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (clinicaltrials.gov) - Nov 18, 2022
P1/2, N=48, Recruiting,
Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Dec 2023 Trial completion date: Sep 2023 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Jan 2025
- |||||||||| NPI-002 / Nacuity Pharma
Trial completion date, Trial primary completion date: NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - Nov 17, 2022
P1/2, N=30, Recruiting,
Trial completion date: Sep 2023 --> Jan 2025 | Trial primary completion date: Sep 2023 --> Jan 2025 Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
- |||||||||| NPI-002 / Nacuity Pharma
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - Mar 16, 2022
P1/2, N=30, Recruiting,
Therefore, further study of NACA and diNACA as potential treatments for cystinosis is warranted. Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Initiation date: Oct 2021 --> Jan 2022 | Trial primary completion date: Jul 2022 --> Dec 2022
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Trial completion date, Trial primary completion date: Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (clinicaltrials.gov) - Sep 9, 2020
P1/2, N=48, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Initiation date: Oct 2021 --> Jan 2022 | Trial primary completion date: Jul 2022 --> Dec 2022 Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- |||||||||| N-acetylcysteine amide (NPI 001) / Nacuity Pharma
Enrollment open, Trial completion date, Trial primary completion date: Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (clinicaltrials.gov) - Jun 30, 2020
P1/2, N=48, Recruiting,
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
|
